Luis Alejandro Acaba-Berrocal

Luis Acaba-Berrocal practices at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.

Luis Acaba-Berrocal's NPI, 1336768852, was assigned on April 14, 2020. Luis Acaba-Berrocal graduated from Jefferson Medical College of Thomas Jefferson University in 2020. Luis Acaba-Berrocal holds Pennsylvania license MD484123.

Luis Acaba-Berrocal's primary practice is Thomas Jefferson University Hospital, at 111 S 11th St, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 955-7106.

Luis Acaba-Berrocal's primary practice is Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Luis Acaba-Berrocal is also affiliated with Wills Eye Hospital. Dmand AI also links Luis Acaba-Berrocal to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Luis Acaba-Berrocal practices. Vendor and product names are available with a free account.

Ophthalmology is Luis Acaba-Berrocal's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Luis Acaba-Berrocal is licensed in Pennsylvania.

CMS data shows 526 Medicare services from Luis Acaba-Berrocal across 9 procedure codes in 2024, for 262 Medicare patients. Medicare paid $60,012 for them. Every service was in an office.

CMS counts 262 Medicare patients who saw Luis Acaba-Berrocal in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Luis Acaba-Berrocal's median patient age at 64, with 48% women.

In 2024, Luis Acaba-Berrocal wrote 289 Medicare Part D claims for 118 patients. 68% of them were for generic drugs. CMS names the drug for 243 of them, across 8 drugs with 11 or more claims each, at $8,441 in total drug cost. In 2023, CMS named 156 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Luis Acaba-Berrocal for performance year 2024, reported as part of a group. Luis Acaba-Berrocal accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Luis Acaba-Berrocal, published from 2019 to 2025. 2022 was the busiest year, with 5. The most frequent topics are Vitrectomy, Angiogenesis Inhibitors and Bevacizumab. Luis Acaba-Berrocal has published most often in Asia Pac J Ophthalmol (Phila). Luis Acaba-Berrocal's most frequent co-authors are Sean Patrick Considine, MD, Caroline Robyn Baumal, MD and Kenneth Chen Fan, MBA, MD.

CMS Open Payments shows 43 general payments to Luis Acaba-Berrocal from 10 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 52% of the total. Bausch & Lomb Americas Inc. paid the most, $2,478. It also lists 2 research payments totaling $1,622 in 2025.

Luis Acaba-Berrocal graduated from Jefferson Medical College of Thomas Jefferson University in 2020.